Medicenna Therapeutics (TSE:MDNA) Hits New 1-Year Low – Time to Sell?

Shares of Medicenna Therapeutics Corp. (TSE:MDNA) hit a new 52-week low during trading on Wednesday . The company traded as low as C$0.60 and last traded at C$0.60, with a volume of 252626 shares changing hands. The stock had previously closed at C$0.65.

Medicenna Therapeutics Trading Up 1.7%

The stock’s 50 day moving average price is C$0.75 and its 200-day moving average price is C$1.01. The company has a quick ratio of 4.65, a current ratio of 2.68 and a debt-to-equity ratio of 3.30. The stock has a market capitalization of C$50.89 million, a PE ratio of -4.07 and a beta of 2.84.

Medicenna Therapeutics (TSE:MDNA) last announced its quarterly earnings data on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. On average, sell-side analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.